AACE retweeted
Endocrine University starts today! @TheAACE
Excited about this educational series, with adrenal lectures featuring expert speakers. I've always been a big fan of EU! @WashUMedEndo
Continuous methimazole for 60+ months showed <20% relapse rate compared to ~50% for standard 12-18 month courses, plus faster TSH normalization, more euthyroid time, fewer orbitopathy flares, and minimal late adverse events.👇🏻
Endocrine Practice Highlight: Long-Term Antithyroid Drug Therapy in the Management of Graves’ Hyperthyroidism: An Updated Narrative Review
Findings showed that patient priorities, efficacy and safety, and higher remission rates could be achieved with long-term (more than) 5 years of antithyroid drug treatment, as compared to other treatment modalities.
Read more: endocrinepractice.org/articl…
@vtangpricha
AACE retweeted
How @GoogleResearch is using wearable data and AI to predict metabolic risk. I did this interview with @aametwally1, metabolic researcher at Google few weeks ago and now we have insulin resistance prediction in @GooglePixel_US Google pixel watch! @TheAACE @AACEMENA @TheEndoSociety @EndocrineToday @AmDiabetesAssn #diabetes aaceendocrine.ai/videos/news…
AACE retweeted
Our paper on the clinical spectrum of #parathyroidcarcinoma is out in AACE Endocrinology and Diabetes!
It was a real team effort. Grateful to our coauthors (@Jessicaabramo) and everyone who contributed, and of course editors at @TheAACE (@vtangpricha)
sciencedirect.com/science/ar…
AACE retweeted
Can physicians create models without writing code? Agentic - no code thyroid nodule risk stratification from ultrasound images. Our latest paper @TheEndoSociety JCEM #Thyroid #EndoTwitter #MedTwitter We used @huggingface ML-Intern to create this model. This democratize model creation. @abidlabs @TheAACE @AmThyroidAssn @ClementDelangue see paper at academic.oup.com/jcem/advanc…
AACE retweeted
As Chair of the AACE Awards Committee, I invite you to nominate a deserving colleague for an @TheAACE Award. Help us recognize the outstanding clinicians, educators, researchers, and leaders who make a difference in endocrinology every day. #WeAreAACE
pro.aace.com/about/aace-awar…
AACE retweeted
💉 2026 AACE Clinical Guidance for the Management of Type 2 Diabetes in Adults
bit.ly/4ypje6h
With @TheAACE, and Allison Rhodes, MD and Alicia Shelly, MD of @OMAsocial
(2/5)
AACE retweeted
Dyslipidemia management is an important part of comprehensive diabetes care and cardiovascular risk reduction.
Dyslipidemia is a major driver of cardiovascular risk in patients with type 2 diabetes (T2D), and lipid management is a key component of the the latest AACE Consensus Statement: Algorithm for Management of Adults with Type 2 Diabetes - 2026 Update. Immediate Past President Scott D. Isaacs, MD, FACP, FACE, reviews new recommendations on LDL-C goals and individualized care in this population. Listen to the podcast at reachmd.com/programs/heart-m….
#WeAreAACE
AACE retweeted
GLP1 receptor agonists, especially #semaglutide, followed by liraglutide & exenatide have excellent safety in people with end stage renal (ESRD) disease on renal replacement therapy.
On an average 7kg weight loss,3kg/m2 reduction in BMI following 1 year therapy with semaglutide in ESRD
Weight loss with GLP1RAs in obese people with ESRD is associated with better outcomes following renal transplant
endocrinepractice.org/articl…
@NephJC @renal_TD @nkf @TheAACE @CVKidneyCare @rssdi @icmr
AACE retweeted
When AI enters endocrine care: Clinical judgment, oversight and legal risk - part 1 aaceendocrine.ai/videos/roun… @TheAACE #AI #endocrinology
AACE retweeted
Practice changing implications in paediatric endocrinology
Aromatase Inhibitors (AI) with Growth Hormone (GH) combination therapy is the best treatment option for improving height outcomes in adolescent boys with short stature (SS) and advanced Bone Age (BA)
AI+GH is superior to the currently considered standard treatment [GnRHa (goserelin/leuprolide)+GH]
Best AI to use is Letrozole followed by Anastrazole
Cost of 3month therapy of Letrozole 2.5mg/day ( INR 2,100/ USD 22)
Cost of 3 month therapy of GnRHa (Goserelin 10.8mg) (INR 28,000/ USD 295)
GnRHa= Gonadotropin receptor agonist
endocrinepractice.org/articl…
@TheAACE @AmerAcadPeds @JAMAPediatrics @CanPaedSociety @pesk_kenya @PedEndoDiabMet @PEndocrinology @ped_endo @adolescenteando @adhdghana @acamh @1adoIescente @IndiaESI @CMEINDIA1 @paedendo @growthhormoneuk @shortstatureegy @SSSS_Org @kunalmahajan4 @abm_kamrul @JenaSweekruti
AACE retweeted
Our latest invited review in Endocrine Practice about application of AI in thyroidology. It was great working with @GonzaloDiazSoto . #AI #Thyroid @TheAACE sciencedirect.com/science/ar…
AACE retweeted
New @TheAACE guidance on managing dyslipidemia in type 2 diabetes is here. In this Heart Matters podcast, I discuss what has changed, including LDL goals, cardiovascular risk reduction, and how to individualize lipid management for our patients with T2D.
reachmd.com/programs/heart-m…
AACE retweeted
The bridge to affordable obesity care opens today, July 1.
Help your Medicare patients access life-changing treatments for a flat $50 monthly copay. Learn the specific administrative workflows and clinical eligibility rules today using OCAN’s provider resources in the comments link.
AACE retweeted
Replying to @TheAACE
#Endo2026 Scott Issacs speaking in MAFLD @TheEndoSociety excellent overview..:::: @aace past president
AACE retweeted
Congratulations to Dr. Sina Jasim on earning the FACE (Fellow of the American Association of Clinical Endocrinology) designation and on her appointment to @TheAACE Board of Directors. These distinguished honors reflect her leadership, expertise, and dedication to the field.
AACE retweeted
ARE YOU READY? 🚦
On July 1, the landscape of obesity care will change significantly with the launch of the @CMSGov GLP-1 Bridge program.
@ObesityAdvocacy @AmDiabetesAssn @ObesityAction @OMAsocial @ASMBS and @ObesitySociety are hosting a critical conversation for patients and clinical teams on how to navigate this new model before launch day.
You can make the difference. Have the conversation with patients, families and caregivers. Join us!
🗓️June 18 ⏰12 PM or 7 PM ET (Live Q&A)
🔗RSVP: obesitycareadvocacynetwork.c…
AACE retweeted
Just like a resident memorizing practice exams, an AI that memorizes training data will fail in the real world. In my latest for @TheAACE Endocrine AI, I explore overfitting, data leakage, and the critical skepticism clinicians need
tinyurl.com/2s3z67vb
@MayoClinicEndo
AACE retweeted
important for clinicians.
This article highlights that subclinical hypothyroidism is relatively common among patients with type 2 diabetes mellitus and that autoimmune thyroid markers, particularly anti-TPO antibodies, are more prevalent in this group compared to non-diabetic controls. Read more: endocrinologydiabetes.org/ar… @vtangpricha







































